| Ytd | -7.63% | |
| 1y | 106.30% |
| Open | 5.81 | Prev Close | 5.73 | Low | 5.53 | High | 5.98 | Mkt Cap | 1.14B |
| Vol | 0.00 | Avg Vol | 1.77M | EPS | -0.56 | P/E | -9.95 | Forward P/E | -19.83 |
| Beta | 0.26 | Short Ratio | 16.45 | Inst. Own | 105.12% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 5.61 | 200-d Avg | 5.46 | 1yr Est | 10.94 |
SVRA News
Savara Inc. (SVRA) is revisited, focusing on its APAP BLA filing progress. The article assesses SVRA
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded
394,528 shares of Common Stock were sold for about $2.24 million on June 22, 2026, at a weighted ave
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical comp
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopha
Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure, wit
[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company fo
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company fo
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
[url="]Savara Inc.[/url] (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company fo
-- Data Were Presented in an Oral Presentation at the American Thoracic Society (ATS) International
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.15) per share which missed the analyst consens
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopha
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical comp
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical comp
-- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (B
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharm
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.13) per share which met the analyst consensus
-- Day 74 Letter Received from the U.S. Food and Drug Administration (FDA) Indicated the Agency Has
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare
-- When Combined with Recently Announced $75M Royalty Financing, the Company Will Have Access to ~$1
Gainers AeroCentury Corp. (NYSE: ACY) jumped 173.2% to close at $9.70 on Thursday. The company re
This morning 279 companies reached new 52-week highs.
Mid-Morning Market Update: Markets Open Higher; Jabil Misses Q2 Estimates
Stocks That Hit 52-Week Lows On Thursday
Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018